跳至主要内容
临床试验/CTRI/2019/06/019912
CTRI/2019/06/019912已完成2 期

AN OPEN LABELLED NON- RANDOMIZED PHASE II COMPARATIVE CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF PATTRU [EXTERNAL THERAPY] AND KEELVAYU NIVARANA CHOORANAM [INTERNAL] FOR AZHAL KEEL VAYU [OSTEOARTHRITIS].

Mohammed Fizel1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年10月7日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Assessment of change from baseline in WOMAC score at day of 48

研究概览

简要总结

STUDY ENROLLMENT:

In this clinical trial, patient reporting at GSMCH,OPD with the clinical symptoms of both knee joint pain, swelling, tenderness, stiffness, crepitation, restricted movement of both knee joint will be clinically examined and enrolled  in the study based on the inclusion and exclusion criteria.

The patient who are to be enrolled in this study will be informed about the     objective of the study, Pattru application, possible outcomes in their own language and terms understandable to them

·        .

·        After ascertaining the patient willingness, consent will be obtained in the informed consent form.

·        Complete clinical history complaints and duration, examination findings-all will be recorded in the prescribed Performa and clinical assessment forms separately. Screening form and laboratory investigation form filled separately.

·         All the patients will be given unique registrations card in which patients registrations number, address, phone number will be entered. Doctors phone number  etc. will be provided in the card  to report in case of emergency.

·        Patients will be advised to undergo trail and appropriate dietary advice will be given according to the patients  perfect understanding.

CONDUCT OF THE  STUDY:

·        The trial drug and therapy will be given continuously for 48 days.

·        OPD patients are requested to visit the hospital daily. Clinical assessment and prognosis will be noted at first and last clinical visit. For IP patients, the drug is provided daily and clinical assessment will be noted daily. Laboratory  investigations will be done in 0th  day and 48th  day of the trail. For IP Patients who are not in positions to stay in the hospital for long time are advised to attend the OPD for further follow up. At the end of the treatment also, the patients are advised to visit the OPD for further 2 months follow up.

·        If any trail patient fails to take the trail drug on the prescribed day or even next day but wants to continue in the trail from the next day he/she will be allowed. But defaulters of one week will not be allowed to continue and will be withdrawn from the study.

DATA MANAGEMENT:

Ø After enrolling the patient in the study, a separate file for each patient will be opened and all forms will be filed in the file. Study number and Patient number will be entered on the top of the file for easy identifications. Whenever the study patients visits OPD during the study period, the respective patient file will be taken and the necessary recordings will be made at the case record form or other suitable form.

Ø The screening form will filed separately.

Ø The Data recordings, and adverse events if any, will be monitored by the HOD and department of pharmacovigilance. All forms will be further scrutinized and no modifications in the results will be permitted for unbiased reports.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • •Patients having symptoms of joint pain of both knee joints, swelling, tenderness, stiffness, crepitation, restricted movements of both knee joints.
  • •Patients who are willing to give blood samples for laboratory investigation .
  • •Patients who are willing to take X-ray before and after treatment.
  • •Patients who are willing to participate in this study with knowledge of potential risks and who are willing to sign the informed consent.

排除标准

  • •Cardiac disease Rheumatoid and other types of arthritis Use of narcotic drugs Pregnant women and lactating mother Trauma, Fracture, Ligament injury Patient with any other serious illness.
  • •Benign and malignant neoplasm Immuno compromised Patients Dermatological issues.

结局指标

主要结局

Assessment of change from baseline in WOMAC score at day of 48

时间窗: 48 days

次要结局

  • Assessment of quality of life by EQ-5D(48 days)

研究者

发起方
Mohammed Fizel
申办方类型
Other [PG Scholar Stipend]

研究点 (1)

Loading locations...

相似试验

CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY... | 临床试验